4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
Reason given: Funding not acquired
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Massachusetts Eye and Ear InfirmaryBoston, United StatesNo longer taking part
Trial details
- Who runs it
- Massachusetts Eye and Ear Infirmary
- Trial code
- NCT03578354
- Record updated
- 1 July 2024
- Original description
This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.Read full original descriptionShow less
Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine
This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.
Inclusion: Severe vestibular migraine (VM).
Exclusion: Taking migraine prophylactic medication or vestibular suppressants; Neurologic or otologic disease other than VM; Psychiatric illness requiring medication; Medical illness including cancer, coronary artery or cerebrovascular disease; Known allergy to one of the test medications; Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures; Pregnant or breast feeding women.